The German company Fresenius Kabi has sealed a worldwide settlement with AbbVie Inc, concerting all pending patent litigations between the two companies. Under the terms of the agreement, Fresenius Kabi’s biosimilar candidate of Humira (adalimumab), could be commercialized in the United States from September 30, 2023.
On 17 October 2018, licenses under the agreement came into effect in certain countries in Europe in which AbbVie owns Intellectual Property. The application for marketing authorization for Humira was submitted by Fresenius Kabi to the European Medicines Agency (EMA) at the end of last year.
Original source in English:
https://www.fresenius.com/7195
